Paraneoplastic intrahepatic cholestasis in supradiaphragmatic classical hodgkin lymphoma successfully treated with brentuximab vedotin: A case report and review of the literature

Επιστημονική δημοσίευση - Άρθρο Περιοδικού uoadl:3020263 18 Αναγνώσεις

Μονάδα:
Ερευνητικό υλικό ΕΚΠΑ
Τίτλος:
Paraneoplastic intrahepatic cholestasis in supradiaphragmatic classical hodgkin lymphoma successfully treated with brentuximab vedotin: A case report and review of the literature
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background: Hepatic dysfunction in patients with classical Hodgkin lymphoma (cHL) is of multifactorial aetiology. Prompt evaluation with laboratory tests and imaging methods is sufficient for diagnosis in most cases. Intrahepatic cholestasis and vanishing bile duct syndrome (VBDS) may complicate cHL as rare paraneoplastic phenomena. Liver biopsy provides crucial evidence of cholestasis, and ductopenia, if present, confirms the diagnosis of VBDS. Case Report: We report on a cHL patient that presented with jaundice and bulky mediastinal disease and unfold the therapeutic dilemmas we confronted. Marked hyperbilirubinemia was successfully reversed with brentuximab vedotin (BV) at a dose of 1.2 mg/kg and the patient was subsequently treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) at full doses, achieving complete metabolic response. A literature review of intrahepatic cholestasis in cHL is also presented based on currently available data with focus on treatment options and clinicopathologic associations. Conclusion: VBDS and intrahepatic cholestasis are rare and potentially fatal complications of cHL. Their prompt recognition and appropriate treatment can dramatically affect cHL patients’ outcome. BV, used at a reduced dose as a bridging therapy, should be considered as a high-priority treatment plan in these challenging cases. © 2021 International Institute of Anticancer Research. All rights reserved.
Έτος δημοσίευσης:
2021
Συγγραφείς:
Papakonstantinou, I.
Kosmidou, M.
Papathanasiou, K.
Koumpis, E.
Kapsali, E.
Milionis, H.
Vassilakopoulos, T.P.
Papoudou-Bai, A.
Hatzimichael, E.
Περιοδικό:
In vivo (Athens, Greece)
Εκδότης:
International Institute of Anticancer Research
Τόμος:
35
Αριθμός / τεύχος:
4
Σελίδες:
1951-1957
Λέξεις-κλειδιά:
amoxicillin plus clavulanic acid; azithromycin; bilirubin; bleomycin; brentuximab vedotin; carbamazepine; clindamycin; cotrimoxazole; cyclophosphamide; dacarbazine; dexamethasone; doxorubicin; ibuprofen; immunoglobulin E; prednisolone; procarbazine; temozolomide; tetracycline derivative; valproic acid; vinblastine; antineoplastic agent; bleomycin; brentuximab vedotin; dacarbazine; doxorubicin; vinblastine, adult; bilirubin blood level; cancer combination chemotherapy; case report; classical Hodgkin lymphoma; clinical article; computer assisted tomography; disease course; disease free survival; drug dose reduction; female; human; hyperbilirubinemia; intrahepatic cholestasis; jaundice; liver biopsy; liver dysfunction; liver failure; male; mediastinum disease; paraneoplastic syndrome; pathogenesis; positron emission tomography-computed tomography; prognosis; Review; syndrome; thorax radiography; treatment response; vanishing bile duct syndrome; complication; Hodgkin disease; intrahepatic cholestasis, Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brentuximab Vedotin; Cholestasis, Intrahepatic; Dacarbazine; Doxorubicin; Hodgkin Disease; Humans; Vinblastine
Επίσημο URL (Εκδότης):
DOI:
10.21873/INVIVO.12462
Το ψηφιακό υλικό του τεκμηρίου δεν είναι διαθέσιμο.